WEB-based GEne SeT AnaLysis Toolkit
 
Translating gene lists into biological insights...
 


User data and parameters: User data: textAreaUpload.txt, Organism: hsapiens, Id Type: ensembl_gene_stable_id, Ref Set: entrezgene, Significance Level: .05, Statistics Test: Hypergeometric, MTC: BH, Minimum: 2

This table lists the enriched KEGG pathways, number of Entrez IDs in your user data set for the pathway, the corresponding Entrez IDs, and the statistics for the enriched pathway.
The statistic column lists:
Finally, the pathway name is linked to KEGG where the user ids are highlighted, the number of user gene ids is linked to a table with information about the user ids, and the Entrez IDs are linked to Entrez Gene.

PathwayName #Gene EntrezGene Statistics
Osteoclast differentiation 44 10288 54209 10859 7046 5532 3937 126014 4688 23533 2209 5336 653361 4790 5293 11027 5970 6688 6850 8792 1536 2213 11006 4689 3460 695 11026 10326 2215 29760 2214 3554 1535 10000 1435 11024 2212 10990 7132 5603 7305 79168 11025 54 1436 C=128;O=44;E=3.98;R=11.06;rawP=8.22e-34;adjP=1.50e-31
Cytokine-cytokine receptor interaction 57 8741 6368 6363 3601 1236 27242 4050 10673 7046 53833 3597 3606 8794 944 5156 51561 1441 4055 1439 58191 1230 3572 11009 7850 23765 1489 3566 8792 5159 2829 5473 6354 3574 3460 23529 1438 8795 3579 6372 729230 3594 3586 3587 80301 355 3554 7133 1435 8807 7132 9180 6357 3559 8740 3577 6362 1436 C=265;O=57;E=8.23;R=6.92;rawP=3.64e-31;adjP=3.33e-29
Staphylococcus aureus infection 26 721 718 5724 2213 6404 720 3684 2357 3426 728 715 3586 2215 2214 2204 713 3689 712 2209 714 2212 716 2359 717 2358 719 C=55;O=26;E=1.71;R=15.21;rawP=7.50e-25;adjP=4.58e-23
Chemokine signaling pathway 39 6368 6363 1236 4067 1794 7409 58191 1230 23533 2793 5580 653361 4790 109 5293 5330 2771 5970 2829 5473 6354 2868 4893 3579 5908 57580 729230 6372 2773 3055 7454 2268 5579 10000 6357 409 3718 3577 6362 C=189;O=39;E=5.87;R=6.64;rawP=4.58e-21;adjP=2.10e-19
Phagosome 33 7280 4360 3684 4481 4688 2204 7057 1520 2209 653361 11151 7099 1536 55176 718 2213 4689 64581 51143 23673 30835 715 929 2215 10333 2214 3689 8685 81035 1535 3673 2212 5878 C=153;O=33;E=4.75;R=6.94;rawP=1.15e-18;adjP=3.01e-17
Chagas disease (American trypanosomiasis) 28 718 3460 2769 7046 3586 10333 2773 8772 5519 355 713 2778 712 23533 10000 4790 714 51135 7132 2776 5603 5054 5293 4615 5330 7099 2771 5970 C=104;O=28;E=3.23;R=8.67;rawP=8.62e-19;adjP=3.01e-17
Leishmaniasis 24 718 4689 3460 5777 3676 3684 65108 3586 2215 4688 2214 3689 1535 2209 5579 1378 653361 51135 4790 2212 5603 4615 5970 7099 C=72;O=24;E=2.24;R=10.73;rawP=1.02e-18;adjP=3.01e-17
B cell receptor signaling pathway 23 2213 4893 4794 5777 3635 695 5532 971 4067 29760 7409 973 23533 118788 5579 10000 5336 4790 27071 5293 5970 11025 6850 C=75;O=23;E=2.33;R=9.87;rawP=4.46e-17;adjP=1.02e-15
Complement and coagulation cascades 22 721 718 720 7035 3426 2162 728 715 730 725 713 5104 5265 712 710 1378 714 716 5054 717 5345 719 C=69;O=22;E=2.14;R=10.26;rawP=8.38e-17;adjP=1.70e-15
Fc gamma R-mediated phagocytosis 24 2213 8936 3635 65108 4067 3055 1794 2214 7409 5788 7454 10095 23533 10092 2209 5579 10000 5580 5336 653361 2212 5293 382 6850 C=94;O=24;E=2.92;R=8.22;rawP=9.80e-16;adjP=1.79e-14
Metabolic pathways 88 9945 4351 9060 7357 54947 11226 7358 55500 586 18 383 151056 125 23761 1040 240 272 5336 220 4124 316 1806 10558 23600 11343 441024 4705 51703 2651 7941 5538 6303 259307 8869 4051 290 5050 10855 10993 5740 8942 2203 2539 211 3067 5214 55907 4837 6652 1723 22856 5373 27306 100 4121 4245 3290 1036 5742 29920 5106 3101 79888 5330 2650 223 3612 2729 5322 6916 64409 29906 10714 27124 9517 5320 5226 2591 29880 55750 6675 5634 3614 2720 34 85365 2686 9536 C=1130;O=88;E=35.11;R=2.51;rawP=4.52e-15;adjP=7.52e-14
Apoptosis 21 839 8795 7157 8737 5532 8794 8772 355 3554 1439 23533 10000 3656 51135 4790 7132 5293 317 4615 5970 5573 C=87;O=21;E=2.70;R=7.77;rawP=2.02e-13;adjP=3.08e-12
Hematopoietic cell lineage 21 3574 920 3676 1438 3684 929 3674 290 1441 3554 951 2209 1378 1435 3673 7850 3566 3559 960 945 1436 C=88;O=21;E=2.73;R=7.68;rawP=2.57e-13;adjP=3.62e-12
Jak-STAT signaling pathway 27 3574 3460 3601 5777 1438 23529 53833 3597 3594 3586 51561 3587 1441 1439 23533 3572 10000 11009 9180 1489 6776 3559 3566 81848 5293 894 3718 C=155;O=27;E=4.82;R=5.61;rawP=3.84e-13;adjP=5.02e-12
Toll-like receptor signaling pathway 21 29110 942 8737 929 10333 3663 51311 8772 6696 23533 10000 51135 4790 5603 23643 3929 5293 4615 5970 7099 7096 C=102;O=21;E=3.17;R=6.63;rawP=5.54e-12;adjP=6.76e-11
Leukocyte transendothelial migration 22 4318 4267 4689 3676 3684 5908 83593 50848 2773 4688 7409 3689 1535 23533 5579 5336 653361 5603 7412 5293 2771 1536 C=116;O=22;E=3.60;R=6.10;rawP=9.84e-12;adjP=1.13e-10
Amoebiasis 21 3915 2769 1286 3684 5272 929 3586 383 2778 3554 3689 23533 5579 4790 7850 2776 5293 5970 7099 5330 5878 C=106;O=21;E=3.29;R=6.38;rawP=1.21e-11;adjP=1.30e-10
Pathways in cancer 35 4318 8325 7157 7046 1026 2113 5156 3674 1441 25 23533 5336 4790 3479 5293 5970 6688 5159 4893 5914 3915 1438 1286 83593 4312 8772 355 5467 5579 3091 10000 3673 6776 6789 1436 C=326;O=35;E=10.13;R=3.46;rawP=2.49e-10;adjP=2.42e-09
Systemic lupus erythematosus 22 721 718 2213 8367 942 720 85236 715 1991 3586 2215 730 2214 713 712 2209 714 2212 716 55506 717 940 C=136;O=22;E=4.23;R=5.21;rawP=2.51e-10;adjP=2.42e-09
Fc epsilon RI signaling pathway 17 4893 2207 3635 5322 695 3937 4067 5320 7409 23533 5579 10000 5336 5580 5603 5293 6850 C=79;O=17;E=2.45;R=6.93;rawP=2.75e-10;adjP=2.52e-09
Toxoplasmosis 20 3915 3460 5322 3586 2773 3587 5320 240 23533 10000 51135 4790 7132 5603 23643 5293 4615 5970 2771 7099 C=132;O=20;E=4.10;R=4.88;rawP=5.23e-09;adjP=4.56e-08
Natural killer cell mediated cytotoxicity 20 10870 4893 2207 3460 5777 8795 5532 8794 3937 2215 2214 355 3689 7409 23533 5579 5336 5293 7305 6850 C=136;O=20;E=4.23;R=4.73;rawP=8.86e-09;adjP=7.37e-08
Long-term depression 14 2778 4893 5579 5322 3479 2776 3709 4067 5330 10672 2773 2771 5519 5320 C=70;O=14;E=2.17;R=6.44;rawP=2.78e-08;adjP=2.21e-07
Lysosome 18 6556 5538 1522 4125 3988 4864 1520 1075 10239 57192 7805 1174 1211 2720 5641 1201 4668 54 C=121;O=18;E=3.76;R=4.79;rawP=4.04e-08;adjP=3.08e-07
Neurotrophin signaling pathway 18 4893 4794 6195 7157 5908 25 23533 10000 5580 51135 4790 3656 5336 396 5603 7534 5293 5970 C=127;O=18;E=3.95;R=4.56;rawP=8.65e-08;adjP=6.33e-07
T cell receptor signaling pathway 16 920 4893 4794 5777 5532 3586 3937 5788 7409 23533 10000 4790 5603 5293 5970 940 C=108;O=16;E=3.36;R=4.77;rawP=2.40e-07;adjP=1.69e-06
MAPK signaling pathway 26 4893 6195 5322 7157 5908 7046 929 5532 5156 355 5320 3554 1616 5579 115727 10000 4790 7132 4296 7850 5603 5536 409 5970 5159 6789 C=268;O=26;E=8.33;R=3.12;rawP=3.62e-07;adjP=2.45e-06
Pancreatic secretion 15 2778 4218 5579 1359 5322 9545 5908 109 2776 483 3709 5874 5330 5320 478 C=101;O=15;E=3.14;R=4.78;rawP=5.48e-07;adjP=3.58e-06
Gap junction 14 2778 1902 7280 4893 5579 109 2776 3709 5330 2773 2771 5156 6714 5159 C=90;O=14;E=2.80;R=5.01;rawP=7.30e-07;adjP=4.61e-06
Rheumatoid arthritis 14 3689 8741 942 1435 4050 10673 6372 4312 3606 51561 7099 8792 940 54 C=91;O=14;E=2.83;R=4.95;rawP=8.39e-07;adjP=5.12e-06
Cell adhesion molecules (CAMs) 17 4267 3689 5788 920 5819 942 6404 3676 25945 3684 57863 6402 7412 50848 23308 6614 940 C=133;O=17;E=4.13;R=4.11;rawP=8.77e-07;adjP=5.18e-06
Acute myeloid leukemia 11 5467 5914 4893 23533 10000 4790 6776 5293 11040 5970 6688 C=57;O=11;E=1.77;R=6.21;rawP=1.24e-06;adjP=7.09e-06
NOD-like receptor signaling pathway 11 84674 114548 64170 29108 4790 64127 3606 5603 5970 4210 9051 C=58;O=11;E=1.80;R=6.10;rawP=1.49e-06;adjP=8.26e-06
Arachidonic acid metabolism 11 240 5740 5322 6916 5742 2686 151056 9536 4051 27306 5320 C=59;O=11;E=1.83;R=6.00;rawP=1.78e-06;adjP=9.58e-06
Shigellosis 11 25 7454 8936 3059 10095 10092 4790 64127 5603 960 5970 C=61;O=11;E=1.90;R=5.80;rawP=2.51e-06;adjP=1.31e-05
Gastric acid secretion 12 2778 5579 3772 109 2776 483 3709 6752 2773 2771 5330 478 C=74;O=12;E=2.30;R=5.22;rawP=2.86e-06;adjP=1.45e-05
Regulation of actin cytoskeleton 21 4893 8936 3676 8826 3684 929 5156 3674 3689 7409 7454 10095 3071 23533 10092 3673 89846 5293 3687 10672 5159 C=213;O=21;E=6.62;R=3.17;rawP=3.62e-06;adjP=1.79e-05
VEGF signaling pathway 12 4893 9047 5579 23533 10000 5336 5322 5603 5532 5293 6714 5320 C=76;O=12;E=2.36;R=5.08;rawP=3.82e-06;adjP=1.84e-05
Glioma 11 4893 5579 23533 10000 5336 7157 3479 5293 1026 5156 5159 C=65;O=11;E=2.02;R=5.45;rawP=4.81e-06;adjP=2.26e-05
p53 signaling pathway 11 83667 8795 7157 3479 5054 11200 317 1026 894 7057 355 C=68;O=11;E=2.11;R=5.21;rawP=7.56e-06;adjP=3.46e-05
Pathogenic Escherichia coli infection 10 25 7280 7454 3059 10095 10092 7534 23643 929 7099 C=56;O=10;E=1.74;R=5.75;rawP=7.87e-06;adjP=3.51e-05
African trypanosomiasis 8 5579 3606 2776 7412 3586 4615 5330 355 C=35;O=8;E=1.09;R=7.36;rawP=9.48e-06;adjP=4.13e-05
Chronic myeloid leukemia 11 25 4893 23533 10000 4790 7157 7046 6776 5293 1026 5970 C=73;O=11;E=2.27;R=4.85;rawP=1.52e-05;adjP=6.13e-05
Amino sugar and nucleotide sugar metabolism 9 55907 9945 4351 6675 7358 80896 5373 3101 1116 C=48;O=9;E=1.49;R=6.03;rawP=1.48e-05;adjP=6.13e-05
Intestinal immune network for IgA production 9 4055 8741 3601 942 3676 10673 3586 23308 940 C=48;O=9;E=1.49;R=6.03;rawP=1.48e-05;adjP=6.13e-05
GnRH signaling pathway 13 2778 4893 5579 5580 5322 4323 109 5603 2776 3709 5330 6714 5320 C=101;O=13;E=3.14;R=4.14;rawP=1.54e-05;adjP=6.13e-05
ErbB signaling pathway 12 27 25 4893 5579 23533 374 10000 5336 6776 1026 5293 6714 C=87;O=12;E=2.70;R=4.44;rawP=1.60e-05;adjP=6.23e-05
Focal adhesion 19 3915 3676 1286 5908 5156 6714 3674 1293 7057 7409 6696 23533 5579 10000 3673 3479 5293 894 5159 C=200;O=19;E=6.21;R=3.06;rawP=1.75e-05;adjP=6.67e-05
Endocytosis 19 2868 116984 1173 23550 3579 2350 7046 5156 6714 64744 23527 1601 1211 3559 382 409 3577 5878 1436 C=201;O=19;E=6.25;R=3.04;rawP=1.88e-05;adjP=7.02e-05
Malaria 9 3689 1378 4035 3606 7412 3586 4615 7099 7057 C=51;O=9;E=1.58;R=5.68;rawP=2.47e-05;adjP=9.04e-05
Non-small cell lung cancer 9 4893 5579 23533 10000 5336 7157 83593 5293 6789 C=54;O=9;E=1.68;R=5.36;rawP=3.97e-05;adjP=0.0001
Aldosterone-regulated sodium reabsorption 8 5579 23533 3290 3479 5293 483 9351 478 C=42;O=8;E=1.30;R=6.13;rawP=3.92e-05;adjP=0.0001
Calcium signaling pathway 17 5025 5737 5724 2769 5137 5532 3709 5156 2778 6869 5579 5336 109 2776 5330 5159 3269 C=177;O=17;E=5.50;R=3.09;rawP=4.15e-05;adjP=0.0001
Small cell lung cancer 11 3915 23533 10000 1286 3673 4790 7157 5293 317 5970 3674 C=85;O=11;E=2.64;R=4.17;rawP=6.51e-05;adjP=0.0002
Carbohydrate digestion and absorption 8 5579 23533 10000 5293 483 5330 3101 478 C=44;O=8;E=1.37;R=5.85;rawP=5.57e-05;adjP=0.0002
Adipocytokine signaling pathway 10 51703 7133 6517 51422 4794 10000 4790 7132 5106 5970 C=68;O=10;E=2.11;R=4.73;rawP=4.59e-05;adjP=0.0002
Ether lipid metabolism 7 5050 7941 151056 79888 54947 5322 5320 C=36;O=7;E=1.12;R=6.26;rawP=0.0001;adjP=0.0003
Prostate cancer 11 4893 23533 10000 4790 7157 3479 5293 1026 5156 5970 5159 C=89;O=11;E=2.77;R=3.98;rawP=9.95e-05;adjP=0.0003
Neuroactive ligand-receptor interaction 21 5025 5737 5724 9170 7067 2743 2357 728 8698 5732 1902 6869 5031 53829 2359 6752 140 3269 150 2358 719 C=272;O=21;E=8.45;R=2.48;rawP=0.0001;adjP=0.0003
Salivary secretion 11 2778 5579 3783 4069 109 2776 483 820 3709 5330 478 C=89;O=11;E=2.77;R=3.98;rawP=9.95e-05;adjP=0.0003
Primary immunodeficiency 7 5788 973 920 3718 29760 100 695 C=35;O=7;E=1.09;R=6.44;rawP=8.63e-05;adjP=0.0003
Phosphatidylinositol signaling system 10 3612 5579 23533 3635 5336 5293 3709 5330 27124 1040 C=78;O=10;E=2.42;R=4.13;rawP=0.0002;adjP=0.0006
Epithelial cell signaling in Helicobacter pylori infection 9 5336 4790 3579 5603 50848 5970 4067 3577 6714 C=68;O=9;E=2.11;R=4.26;rawP=0.0002;adjP=0.0006
Protein digestion and absorption 10 9056 1359 206358 3783 1286 7512 483 6510 1293 478 C=81;O=10;E=2.52;R=3.97;rawP=0.0002;adjP=0.0006
Bacterial invasion of epithelial cells 9 7454 8936 3059 10095 10092 23533 1211 5293 6714 C=70;O=9;E=2.17;R=4.14;rawP=0.0003;adjP=0.0008
Hepatitis C 13 29110 4893 23533 10000 4790 7157 7132 8737 5603 5293 1026 5970 5519 C=134;O=13;E=4.16;R=3.12;rawP=0.0003;adjP=0.0008
Melanoma 9 4893 23533 10000 7157 3479 5293 1026 5156 5159 C=71;O=9;E=2.21;R=4.08;rawP=0.0003;adjP=0.0008
Adherens junction 9 4008 7454 8936 5819 5777 25945 8826 7046 6714 C=73;O=9;E=2.27;R=3.97;rawP=0.0004;adjP=0.0011
Fructose and mannose metabolism 6 4351 3101 5373 6652 2203 5214 C=36;O=6;E=1.12;R=5.36;rawP=0.0008;adjP=0.0021
Tight junction 12 23136 4893 3059 5579 10000 5580 50848 2773 2771 6714 5519 6709 C=132;O=12;E=4.10;R=2.93;rawP=0.0009;adjP=0.0024
Vascular smooth muscle contraction 11 2778 5579 5580 5322 109 2776 3709 72 10672 5330 5320 C=116;O=11;E=3.60;R=3.05;rawP=0.0010;adjP=0.0026
ECM-receptor interaction 9 6696 3915 3676 1286 3673 960 1293 3674 7057 C=85;O=9;E=2.64;R=3.41;rawP=0.0013;adjP=0.0031
Amyotrophic lateral sclerosis (ALS) 7 7133 5603 5532 317 1616 7157 7132 C=53;O=7;E=1.65;R=4.25;rawP=0.0012;adjP=0.0031
Pantothenate and CoA biosynthesis 4 8875 586 1806 8876 C=16;O=4;E=0.50;R=8.05;rawP=0.0013;adjP=0.0031
Pentose phosphate pathway 5 2539 2203 5634 5214 5226 C=27;O=5;E=0.84;R=5.96;rawP=0.0013;adjP=0.0031
Insulin signaling pathway 12 6517 51422 4893 23533 10000 3635 2203 2997 5293 5106 3101 5573 C=138;O=12;E=4.29;R=2.80;rawP=0.0013;adjP=0.0031
Progesterone-mediated oocyte maturation 9 23533 10000 6195 3479 109 5603 5293 2773 2771 C=86;O=9;E=2.67;R=3.37;rawP=0.0014;adjP=0.0033
Long-term potentiation 8 4893 5579 6195 5908 2776 3709 5532 5330 C=70;O=8;E=2.17;R=3.68;rawP=0.0015;adjP=0.0035
Bladder cancer 6 4318 4312 1026 4893 7157 7057 C=42;O=6;E=1.30;R=4.60;rawP=0.0018;adjP=0.0042
Valine, leucine and isoleucine degradation 6 259307 586 34 18 223 316 C=44;O=6;E=1.37;R=4.39;rawP=0.0023;adjP=0.0053
Axon guidance 11 25 23380 10501 4893 1969 1944 1946 5532 2773 2771 2242 C=129;O=11;E=4.01;R=2.74;rawP=0.0024;adjP=0.0054
Glycerophospholipid metabolism 8 54947 5322 55500 79888 151056 23761 5320 1040 C=80;O=8;E=2.49;R=3.22;rawP=0.0034;adjP=0.0076
N-Glycan biosynthesis 6 29880 85365 4245 91869 4121 4124 C=49;O=6;E=1.52;R=3.94;rawP=0.0040;adjP=0.0087
Glycolysis / Gluconeogenesis 7 5106 3101 125 2203 5214 220 223 C=65;O=7;E=2.02;R=3.47;rawP=0.0040;adjP=0.0087
beta-Alanine metabolism 4 34 18 1806 223 C=22;O=4;E=0.68;R=5.85;rawP=0.0043;adjP=0.0090
Melanogenesis 9 2778 4893 5579 8325 109 2776 2773 2771 5330 C=101;O=9;E=3.14;R=2.87;rawP=0.0043;adjP=0.0090
Prion diseases 5 713 712 3915 730 714 C=35;O=5;E=1.09;R=4.60;rawP=0.0043;adjP=0.0090
Proximal tubule bicarbonate reclamation 4 483 5106 478 1468 C=23;O=4;E=0.71;R=5.60;rawP=0.0051;adjP=0.0106
mTOR signaling pathway 6 5293 3091 23533 10000 6195 3479 C=52;O=6;E=1.62;R=3.71;rawP=0.0054;adjP=0.0111
Pancreatic cancer 7 7046 5293 5970 23533 10000 4790 7157 C=70;O=7;E=2.17;R=3.22;rawP=0.0060;adjP=0.0119
Nicotinate and nicotinamide metabolism 4 54981 4837 83594 316 C=24;O=4;E=0.75;R=5.36;rawP=0.0060;adjP=0.0119
Renal cell carcinoma 7 4893 5293 2113 3091 23533 10000 5908 C=70;O=7;E=2.17;R=3.22;rawP=0.0060;adjP=0.0119
RIG-I-like receptor signaling pathway 7 8737 5603 29110 5970 7706 4790 8772 C=71;O=7;E=2.21;R=3.17;rawP=0.0065;adjP=0.0128
Dilated cardiomyopathy 8 2778 3676 3673 7171 3479 109 4000 3674 C=90;O=8;E=2.80;R=2.86;rawP=0.0070;adjP=0.0136
Sphingolipid metabolism 5 2720 10558 7357 9517 81537 C=40;O=5;E=1.24;R=4.02;rawP=0.0077;adjP=0.0147
Cytosolic DNA-sensing pathway 6 8737 3606 29110 5970 29108 4790 C=56;O=6;E=1.74;R=3.45;rawP=0.0077;adjP=0.0147
Inositol phosphate metabolism 6 3612 5293 27124 5330 5336 253430 C=57;O=6;E=1.77;R=3.39;rawP=0.0084;adjP=0.0158
Tryptophan metabolism 5 259307 10352 8942 223 316 C=42;O=5;E=1.30;R=3.83;rawP=0.0094;adjP=0.0176
Glycosphingolipid biosynthesis - ganglio series 3 2720 29906 8869 C=15;O=3;E=0.47;R=6.44;rawP=0.0103;adjP=0.0190
Vasopressin-regulated water reabsorption 5 2778 109 51143 5878 396 C=44;O=5;E=1.37;R=3.66;rawP=0.0114;adjP=0.0209
Primary bile acid biosynthesis 3 23600 9420 10858 C=16;O=3;E=0.50;R=6.03;rawP=0.0124;adjP=0.0225
Mucin type O-Glycan biosynthesis 4 2591 64409 11226 2650 C=30;O=4;E=0.93;R=4.29;rawP=0.0134;adjP=0.0240
Hypertrophic cardiomyopathy (HCM) 7 51422 3676 3674 3673 4000 7171 3479 C=83;O=7;E=2.58;R=2.71;rawP=0.0148;adjP=0.0263
Type II diabetes mellitus 5 6517 5293 3101 23533 5580 C=48;O=5;E=1.49;R=3.35;rawP=0.0163;adjP=0.0287
Glutathione metabolism 5 2686 2729 2539 290 5226 C=50;O=5;E=1.55;R=3.22;rawP=0.0192;adjP=0.0335
RNA transport 10 11097 54913 10762 8665 10284 348995 10289 26986 81929 55916 C=151;O=10;E=4.69;R=2.13;rawP=0.0199;adjP=0.0344
PPAR signaling pathway 6 4312 51703 5467 34 5106 5360 C=70;O=6;E=2.17;R=2.76;rawP=0.0216;adjP=0.0369
Endometrial cancer 5 4893 5293 23533 10000 7157 C=52;O=5;E=1.62;R=3.09;rawP=0.0224;adjP=0.0380
Bile secretion 6 2778 109 8714 483 366 478 C=71;O=6;E=2.21;R=2.72;rawP=0.0230;adjP=0.0383
alpha-Linolenic acid metabolism 3 151056 5322 5320 C=20;O=3;E=0.62;R=4.83;rawP=0.0230;adjP=0.0383
Oocyte meiosis 8 6195 3479 109 7534 3709 5532 5519 26271 C=112;O=8;E=3.48;R=2.30;rawP=0.0237;adjP=0.0391
Vibrio cholerae infection 5 2778 109 5579 5336 55176 C=54;O=5;E=1.68;R=2.98;rawP=0.0259;adjP=0.0419
Starch and sucrose metabolism 5 2997 283209 11181 3101 7358 C=54;O=5;E=1.68;R=2.98;rawP=0.0259;adjP=0.0419
Allograft rejection 4 3586 942 940 355 C=37;O=4;E=1.15;R=3.48;rawP=0.0272;adjP=0.0437
Glycosaminoglycan biosynthesis - chondroitin sulfate 3 22856 50515 51363 C=22;O=3;E=0.68;R=4.39;rawP=0.0297;adjP=0.0473


WebGestalt is currently developed and maintained by Jing Wang and Bing Zhang at the Zhang Lab. Other people who have made significant contribution to the project include Dexter Duncan, Stefan Kirov, Zhiao Shi, and Jay Snoddy.

Funding credits: NIH/NIAAA (U01 AA016662, U01 AA013512); NIH/NIDA (P01 DA015027); NIH/NIMH (P50 MH078028, P50 MH096972); NIH/NCI (U24 CA159988); NIH/NIGMS (R01 GM088822).